Personalized Cancer Medicine: Are We There Yet?
Eileen Dolan, PhD
Professor of Medicine, Section of Hematology/Oncology
Co-Director, Clinical and Experimental Therapeutics Program of the Comprehensive Cancer Center
University of Chicago, Illinois
A public lecture in the Distinguished Scholars Series
A primary aim of pharmacogenomics is to devise personalized treatment strategies based on an individual's genetic makeup to maximize the potential for therapeutic benefit and minimize the risk of adverse side effects. Dr. Dolan will discuss the role of pharmacogenomics in cancer research, a field in which personalized drug therapy is especially desirable given the narrow therapeutic index and life-threatening consequences of drug toxicity.
Live Webcast: http://research.vtc.vt.edu/live-webcast
A public reception will be held in the VTC Cafe at 5:00 p.m.
Hosted by: Michael J. Friedlander, PhD, Executive Director, Virginia Tech Carilion Research Institute